Top

Published in:

01-10-2018 | Brief Communication

Ipilimumab treatment associated with myasthenic crises and unfavorable disease course

Authors: Eda Derle, Sibel Benli

Published in: Neurological Sciences | Issue 10/2018

Abstract

Ipilimumab, a monoclonal antibody targeting the cytotoxic T lymphocyte antigen-4 is a treatment option for metastatic melanoma. This receptor serves as an inhibitor receptor on T lymphocytes and blockage of these results predisposition to autoimmune diseases. The patients with autoimmune disorders were excluded in clinical trials and there is no sufficient data of the treatment on these patients who already have an autoimmune disorder. Here, we report a case of myasthenia gravis who was treated with ipilimumab and we presented the long-term prognosis of the patient after treatment.

Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13:211. https://doi.org/10.1186/s12916-015-0455-8 CrossRefPubMedPubMedCentral

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2(2):234–240. https://doi.org/10.1001/jamaoncol.2015.4368 CrossRefPubMed

Kolb NA, Trevino CR, Waheed W, Sobhani F, Landry KK, Thomas AA, Hehir M (2018) Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. https://doi.org/10.1002/mus.26070 CrossRef

Makarious D, Horwood K, Coward JIG (2017) Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 82:128–136. https://doi.org/10.1016/j.ejca.2017.05.041 CrossRefPubMed

Perez-De-Lis M, Retamozo S, Flores-Chavez A, Kostov B, Perez-Alvarez R, Brito-Zeron P, Ramos-Casals M (2017) Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS registry). Expert Opin Drug Saf 16(11):1255–1271. https://doi.org/10.1080/14740338.2017.1372421 CrossRefPubMed

Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG (2001) Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 166(10):6430–6436CrossRefPubMed

Zhu J, Li Y (2016) Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve 54(3):506–507. https://doi.org/10.1002/mus.25055 CrossRefPubMed

Title: Ipilimumab treatment associated with myasthenic crises and unfavorable disease course
Authors: Eda Derle
Sibel Benli
Publication date: 01-10-2018
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 10/2018
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-018-3471-6

At a glance: The STEP trials

Springer Medicine

Ipilimumab treatment associated with myasthenic crises and unfavorable disease course

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2018

A novel compound heterozygous mutation of the L2HGDH gene in a Chinese boy with L-2-hydroxyglutaric aciduria: case report and literature review

Allele-specific methylation contributed by CpG-SNP is associated with regulation of ALOX5AP gene expression in ischemic stroke

Circulating miR-126 and miR-130a levels correlate with lower disease risk, disease severity, and reduced inflammatory cytokine levels in acute ischemic stroke patients

Letter to the editor: lung metastasis in WHO grade I meningioma

Estimating dementia cases in the immigrant population living in Italy

The serum level of inflammatory markers in chronic and episodic migraine: a case-control study